Department of Orthopedic Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, China.
J Orthop Surg Res. 2020 Sep 21;15(1):432. doi: 10.1186/s13018-020-01783-7.
Plantar fasciopathy (PF) is a very common disease, affecting about 1/10 people in their lifetime. Platelet-rich plasma (PRP) had been demonstrated to be useful in achieving helpful effects for plantar fasciopathy. The purpose of this study was to compare the pain and functional outcomes between PRP and corticosteroid (CS) or placebo for plantar fasciopathy through meta-analysis and provide the best evidence.
Literature was searched systematically to explore related studies that were published in Cochrane Library, PubMed, Embase, Medline, SpringerLink, OVID, and ClinicalTrials.gov . Articles regarding comparative research about the outcomes of PRP therapy and CS or placebo injection were selected. Data of pain and functional outcomes was extracted and imported into Reviewer Manager 5.3 to analyze.
Thirteen RCTs were included and analyzed. Analysis results showed significant superiority of PRP in outcome scores when compared with CS (VAS: MD = - 0.85, P < 0.0001, I = 85%; AOFAS: MD = 10.05, P < 0.0001, I = 85%), whereas there is no statistical difference in well-designed double-blind trials (VAS: MD = 0.15, P = 0.72, I = 1%; AOFAS: MD = 2.71, P = 0.17, I = 0%). In the comparison of the PRP and the placebo, the pooled mean difference was - 3.76 (P < 0.0001, 95% CI = - 4.34 to - 3.18).
No superiority of PRP had been found in well-designed double-blind studies, whereas it is implied that the outcomes of PRP are better than placebo based on available evidence.
足底筋膜炎（PF）是一种非常常见的疾病，大约每 10 个人中就有 1 人会患病。富含血小板的血浆（PRP）已被证明对足底筋膜炎有帮助。本研究的目的是通过荟萃分析比较 PRP 与皮质类固醇（CS）或安慰剂治疗足底筋膜炎的疼痛和功能结果，提供最佳证据。
系统搜索 Cochrane 图书馆、PubMed、Embase、Medline、SpringerLink、OVID 和 ClinicalTrials.gov 以查找相关研究，选择关于 PRP 治疗与 CS 或安慰剂注射结果的比较研究。提取和导入数据到 Reviewer Manager 5.3 以进行分析。
纳入并分析了 13 项 RCT。分析结果表明，与 CS 相比，PRP 在结局评分方面具有显著优势（VAS：MD = -0.85，P < 0.0001，I = 85%；AOFAS：MD = 10.05，P < 0.0001，I = 85%），而在设计良好的双盲试验中没有统计学差异（VAS：MD = 0.15，P = 0.72，I = 1%；AOFAS：MD = 2.71，P = 0.17，I = 0%）。在 PRP 与安慰剂的比较中，合并均数差为-3.76（P < 0.0001，95%CI = -4.34 至 -3.18）。
在设计良好的双盲研究中未发现 PRP 的优势，但基于现有证据，PRP 的结果优于安慰剂。
